USE OF IL-2 GENE-TRANSFER IN LOCAL IMMUNOTHERAPY OF CANCER

BUBENIK J LOTZOVA E INDROVA M SIMOVA J JANDLOVA T BUBENIKOVA D

J. Bubenik et al., USE OF IL-2 GENE-TRANSFER IN LOCAL IMMUNOTHERAPY OF CANCER, Cancer letters, 62(3), 1992, pp. 257-262

26

INGLESE

Article

Cancer letters → ACNP

0304-3835

62

3

1992

257 - 262

ISI

0304-3835(1992)62:3<257:UOIGIL>2.0.ZU;2-7

Insertion of functional interleukin-2 (IL-2) gene into a plasmacytoma cell line X63-Ag8.653 substantially reduced tumorigenicity of the resu lting cloned cells, designated as X63-m-IL-2. Peritumoral administrati on of the X63-m-IL-2 cells, producing constitutively large quantities of IL-2, resulted in regressions of established X63-Ag8.653 plasmacyto mas growing in the peritoneal cavity of syngeneic mice. In vitro activ ation of BALB/c spleen cells by co-culture with X63-m-IL-2 cells or th eir supernatants gave rise to cytotoxic lymphocytes with lymphokine-ac tivated killer (LAK) activity against syngeneic X63-Ag8.653 plasmacyto ma and other tumor targets. In contrast, peritumoral administration of X63-Ag8.653 cells carrying an inserted interleukin-4 (IL-4) gene (des ignated X63-m-IL-4 cells) and producing constitutively large quantitie s of IL-4 did not result in a therapeutic effect. Moreover, the admixt ure of the X63-m-IL-4 and X63-m-IL-2 cells substantially diminished th e X63-m-IL-2 cell-mediated therapeutic effect. Similarly, IL-4-contain ing supernatants generated from X63-m-IL-4 cell cultures substantially diminished LAK activation by X63-m-IL-2 cell produced supernants.